Cancer Steering Committee

The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.

Gary Kelloff, M.D., NIH/NCI, (Co-Chair)

Geoff Oxnard, M.D., Foundation Medicine (Co-Chair)

Emmett Schmidt, M.D., Ph.D., Merck (Co-Chair)

Alexandre Akoulitchev, Ph.D., Oxford Biodynamics

Jeff Allen, Ph.D., Friends of Cancer Research

Daniel Auclair, Ph.D., AstraZeneca

Christopher Below, Ph.D., Biognosys

Michelle Berny-Lang, Ph.D., NCI

Donald A. Berry, Ph.D., MD Anderson Cancer Center

Vikram Bhadrasain, M.D., NCI

Jonathan Blackburn, Ph.D., Sengenics

Mohan Bolisetty, Ph.D., Bristol-Meyers Squibb

Gary Borzillo, Ph.D., Janssen

Anita Boyapati, Ph.D., Regeneron

Claudio Carini, Ph.D., Kings College London

Hearn Jay Cho, M.D., Ph.D., The Multiple Myeloma Research Foundation

Caroline Chung, M.D., MD Anderson (QIBA-RSNA)

Steven Cole, NCI

Cecile Combeau, Ph.D., Sanofi

Ellie Corigliano, Ph.D., GlaxoSmithKline

Adam Corner, BioRad

Craig Cummings, Ph.D., Genentech

DeAunne Denmark, M.D., Ph.D., Somalogic

Michelle Douglas, Ph.D., Genentech

Jeff Ecsedy, Ph.D., Ikena Oncology

Michael Espey, Ph.D., NCI

Steven Gendreau, Ph.D., Genentech

Giuseppe Giaccone, M.D., Ph.D., Amgen

Ida Grundberg, Ph.D., Olink

Stanley R. Hamilton, M.D., City of Hope National Medical Center

Sean Hanlon, Ph.D., NCI

Lyndsay Harris, M.D., NCI

Stephanie Hennek, Ph.D., PathAI

James Hnatyszyn, Ph.D., Seattle Genetics, Inc.

Steffan Ho, M.D., Ph.D., Pfizer

Rob Iannone, M.D., Jazz Pharmaceuticals

Peter Intile, SITC

Taylor Jensen, Ph.D., LabCorp

John Jessup, M.D., Institute for Bioscience and Biotechnology Research

Maria Jure-Kunkel, Ph.D., Genmab US, Inc.

Jayaprakash Karkera, Ph.D., GlaxoSmithKline

Morten Karsdal, Ph.D., Nordic Bioscience

Ilan (Lanny) Kirsch, M.D., Adaptive Biotechnologies

Tracy Lively, Ph.D., NIH/NCI

Kate Lyden, Ph.D., VivoSense

Derek McCartney, M.S., Biognosys

Robert McCormack, Ph.D.

Mark Messenbaugh, J.D., SomaLogic

Jen Mills, Ph.D., Foundation Medicine

Mike Montalto, Ph.D., PathAI

Helen Moore, Ph.D., NIH/NCI

Larry Nagahara, Ph.D., John’s Hopkins University

Tanya Nguyen, Ph.D., Sapient Bioanalytics

Michael O’Neal, M.D., BioClinica, Inc.

Mariaelena Occhipinti, Ph.D., Radiomics

Snehal Patel, Ph.D., Association for Molecular Pathology

Reena Philip, Ph.D., FDA/OCE

Vladimir Popov, Ph.D., FNLCR/NCI

Scott Knowles Pruitt, M.D., Ph.D.,Merck

Elizabeth Punnoose, Ph.D., Genentech

Anita Reddy, Ph.D., Amgen

Henry Rodriguez, Ph.D., NIH/NCI

Vanessa Rodrik-Outmezguine, Ph.D., Eli Lilly & Company

Marijana Rucevic, Ph.D., Olink Proteomics

Amy Kate Sasser, Ph.D., Genmab US, Inc.

Julie Schneider Ph.D., FDA/OCE

Lawrence Schwartz, M.D., Memorial Sloan Kettering

Maggie Scully, Ph.D.,Frederick Natl. Lab. For Cancer Research

Alex Snyder, Ph.D., Generate Biomedicines (SITC)

Howard Spiegel, Olink Proteomic

Magadelena Thurin, Ph.D., NIH/NCI

Peter Ujhazy, M.D., Ph.D., NIH/NCI

Tamar Uziel, Ph.D., AbbVie

Megann Vaughn, M.B.A., LabCorp

Tiffany Vines, Olink Proteomics

Wim Vos. Ph.D., Radiomics

Sean Walsh, Ph.D., Radiomics

Tony Wagner, Ph.D., Jazz Pharmaceuticals

Christine Ward, Ph.D., Takeda Pharmaceuticals International, Inc.

Mike Ward, Ph.D., Alector

Mickey Williams, Ph.D., NIH/NCI